Patents by Inventor Minquan Yu
Minquan Yu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250230129Abstract: The present invention relates to the field of medicines, particularly to synthetic polyamide compounds represented by formulas IA, IB, and IC, or pharmaceutically acceptable salts and stereoisomers thereof, a composition containing same, a method for preparing same, and use thereof in the field of medicines.Type: ApplicationFiled: March 22, 2023Publication date: July 17, 2025Applicant: JIANGSU NHWA PHARMACEUTICAL CO., LTDInventors: Yuanyuan HOU, Xiangqing XU, Minquan YU, Song ZHAO, Qiang GUO, Wei WANG, Datong ZHANG, Pengwen FENG, Qidong CHENG, Ao WANG, Xiaojing HE, Changda XU, Yingying DONG, Yinli QIU, Aijun LU, Jianhui CHEN
-
Publication number: 20250070500Abstract: A cable assembly, configured to be mounted to a circuit board having a first conductive pad and a second conductive pad, includes a first cable, a second cable and a support member. The first cable includes a first core, a first insulator and a first shielding layer. The second cable includes a second core, a second insulator and a second shielding layer. The first core and the second core are configured to be in contact with the first conductive pad and the second conductive pad. The support member includes a support portion. The support portion is configured to support the first insulator and the second insulator. The connection portion is in contact with the first shielding layer and the second shielding layer. A cable connector having the cable assembly is also disclosed.Type: ApplicationFiled: April 29, 2024Publication date: February 27, 2025Applicant: Luxshare Precision Industry Company LimitedInventors: Cheng-Kai LIAO, Wei WANG, Minquan YU, Po-Chang HUANG, Ming-Yu HO
-
Publication number: 20230132621Abstract: 1,5-dihydro-2,4-benzodiazepine-3-one derivatives, such as a compound represented by formula I, acts on 5-HT2A and 5-HT2C receptors. The selectivity for 5-HT2A is superior or similar to pimavanserin. The derivative is used for treating schizophrenia or Parkinson’s disease, dementia-related behavioral disorders, and psychosis. The antipsychotic activity of the compound is equivalent to that of pimavanserin, the side effects of sedation and and worsening of exercise are less than those of pimavanserin, and cardiotoxicity is less than that of pimavanserin.Type: ApplicationFiled: October 20, 2022Publication date: May 4, 2023Inventors: Xiangqing XU, Yinli QIU, Qiang GUO, Minquan YU, Song ZHAO, Quxiang LI, Peng JING, Yuanyuan HOU, Yingying DONG, Guosheng WU, Shuang ZHANG, Aijun LU
-
Patent number: 10517862Abstract: The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of general formula (I), and can be used to treat neuropsychiatric diseases.Type: GrantFiled: October 26, 2016Date of Patent: December 31, 2019Assignees: NHWA PHARMA. CORPORATION, WUHAN JIAYU TECHNOLOGY CO., LTD.Inventors: Guisen Zhang, Xudong Cao, Yin Chen, Yifang Zhang, Minquan Yu, Yinli Qiu, Xiangqing Xu, Tan Zhang, Bifeng Liu, Xin Liu
-
Patent number: 10501452Abstract: The present invention relates to a lactam compound derivative, a medicine composition comprising the lactam compound derivative, and uses of the composition and the lactam compound derivative in preparation of a medicine for preventing or treating schizophrenia, the lactam compound derivative having a structure as shown in Formula I.Type: GrantFiled: November 21, 2016Date of Patent: December 10, 2019Assignee: NHWA PHARMA. CORPORATIONInventors: Yin Chen, Fei Dou, Yinli Qiu, Minquan Yu, Guisen Zhang
-
Publication number: 20180327397Abstract: The present invention relates to a lactam compound derivative, a medicine composition comprising the lactam compound derivative, and uses of the composition and the lactam compound derivative in preparation of a medicine for preventing or treating schizophrenia, the lactam compound derivative having a structure as shown in Formula I.Type: ApplicationFiled: November 21, 2016Publication date: November 15, 2018Inventors: Yin CHEN, Fei DOU, Yinli QUI, Minquan YU, Guisen ZHANG
-
Publication number: 20180318286Abstract: The present invention relates to the field of pharmaceutical chemistry, and specifically relates to a fused heterocyclic compound derivative and an application thereof. The fused heterocyclic compound derivative has the structure of general formula (I), and can be used to treat neuropsychiatric diseases.Type: ApplicationFiled: October 26, 2016Publication date: November 8, 2018Inventors: Guisen Zhang, Xudong Cao, Yin Chen, Yifang Zhang, Minquan Yu, Yinli Qiu, Xiangqing Xu, Tan Zhang, Bifeng Liu, Xin Liu
-
Patent number: 9315496Abstract: The present invention relates to the field of pharmaceutical chemistry, and in particular, to a benzopyrone derivative and a use thereof. The benzopyrone derivative is compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof. It has been found by experiments that, this type of compounds is useful in prevention or treatment of neuropsychical diseases.Type: GrantFiled: April 6, 2012Date of Patent: April 19, 2016Assignees: HUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY, NHWA PHARMA CORPORATIONInventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Bifeng Liu, Xin Liu, Song Zhao, Shicheng Liu, Minquan Yu, Heng Zhang, Xinghua Liu
-
Patent number: 9238632Abstract: Disclosed in the present invention is a 3-cyanoanilinoalkylarylpiperazine derivatives and use thereof in preparing drugs; the 3-cyanoanilinoalkylarylpiperazine derivatives disclosed by the present invention has very useful pharmaceutical properties and good tolerance, especially the use as novel analgesic drugs, novel antidepressants, and novel analgesic and antidepressive drugs. This class of compounds are central analgesics regulating 5-hydroxytrptamine, and also are novel antidepressants regulating 5-hydroxytrptamine. This class of compounds also has less toxic and side effects and a higher safety range.Type: GrantFiled: April 9, 2013Date of Patent: January 19, 2016Assignees: NHWA Pharma, Corporation, Shanghai Institute of Pharmaceutical IndustryInventors: Jianqi Li, Guan Wang, Guisen Zhang, Yali Li, Xiangqing Xu, Xiaowen Chen, Shicheng Liu, Song Zhao, Minquan Yu
-
Patent number: 9018213Abstract: Disclosed are alicyclic[c]benzopyrone derivatives and use thereof. The alicyclic[c]benzopyrone derivatives are compounds represented by formula I or their salts. The present compounds not only significantly improve high activity induced by MK-801, but also effectively improve clambering symptom induced by Apomorphine and do not cause EPS within effective dose. These in vitro targets and in vivo pharmacological models are closely related to diseases of the nervous system caused by dopamine dysfunction, especially schizophrenia. Therefore the present compounds can be used for the treatment of central nervous system diseases, especially schizophrenia. ED50 is lower and effect is stronger in two animal models i.e. high activity induced by MK-801 and clambering symptom induced by Apomorphine, while ED50 is higher and therapeutic index is greater in animal models of catalepsy.Type: GrantFiled: July 31, 2012Date of Patent: April 28, 2015Assignees: Huazhong University of Science & Technology, NHWA Pharma. CorporationInventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Xin Liu, Song Zhao, Bifeng Liu, Minquan Yu, Yinli Qiu
-
Publication number: 20150105399Abstract: Disclosed in the present invention is a 3-cyanoanilinoalkylarylpiperazine derivatives and use thereof in preparing drugs; the 3-cyanoanilinoalkylarylpiperazine derivatives disclosed by the present invention has very useful pharmaceutical properties and good tolerance, especially the use as novel analgesic drugs, novel antidepressants, and novel analgesic and antidepressive drugs. This class of compounds are central analgesics regulating 5-hydroxytrptamine, and also are novel antidepressants regulating 5-hydroxytrptamine. This class of compounds also has less toxic and side effects and a higher safety range.Type: ApplicationFiled: April 9, 2013Publication date: April 16, 2015Inventors: Jianqi Li, Guan Wang, Guisen Zhang, Yali Li, Xiangqing Xu, Xiaowen Chen, Shicheng Liu, Song Zhao, Minquan Yu
-
Patent number: 8993575Abstract: The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system.Type: GrantFiled: April 1, 2012Date of Patent: March 31, 2015Assignees: Huazhong University of Science & Technology, NHWA Pharma CorporationInventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Bifeng Liu, Xiaojun Feng, Song Zhao, Shicheng Liu, Minquan Yu, Yu Lan, Yinli Qiu
-
Publication number: 20140113911Abstract: The present invention relates to the field of pharmaceutical chemistry, and in particular, to a benzopyrone derivative and a use thereof. The benzopyrone derivative is compound having a structure of formula (I) or a pharmaceutically acceptable salt thereof. It has been found by experiments that, this type of compounds is useful in prevention or treatment of neuropsychical diseases.Type: ApplicationFiled: April 6, 2012Publication date: April 24, 2014Applicant: NHWA PHARMA CORPORATIONInventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Bifeng Liu, Xin Liu, Song Zhao, Shicheng Liu, Minquan Yu, Heng Zhang, Xinghua Liu
-
Publication number: 20140024656Abstract: The present invention belongs to the medicinal chemistry field, and specifically discloses a [1,3,4]oxadiazole derivative with the structure of general formula (I) and pharmaceutically acceptable salt thereof. The compound can be used to prepare a medicine for preventing or treating a disease of the central nervous system.Type: ApplicationFiled: April 1, 2012Publication date: January 23, 2014Applicant: HUAZHONG UNIVERSITY OF SCIENCE & TECHNOLOGY NHWA PHARMA CORPORATIONInventors: Guisen Zhang, Yin Chen, Xiangqing Xu, Bifeng Liu, Xiaojun Feng, Song Zhao, Shicheng Liu, Minquan Yu, Yu Lan, Yinli Qiu